These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8101414)

  • 1. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application.
    Birkmayer JG; Vrecko C; Volc D; Birkmayer W
    Acta Neurol Scand Suppl; 1993; 146():32-5. PubMed ID: 8101414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.
    Kuhn W; Müller T; Winkel R; Danielczik S; Gerstner A; Häcker R; Mattern C; Przuntek H
    J Neural Transm (Vienna); 1996; 103(10):1187-93. PubMed ID: 9013405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients.
    Birkmayer W; Birkmayer GJ; Vrecko K; Mlekusch W; Paletta B; Ott E
    J Neural Transm Park Dis Dement Sect; 1989; 1(4):297-302. PubMed ID: 2597315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Parkinson's disease with NADH.
    Dizdar N; Kågedal B; Lindvall B
    Acta Neurol Scand; 1994 Nov; 90(5):345-7. PubMed ID: 7887134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nicotinamidadenindinucleotide (NADH): the new approach in the therapy of Parkinson's disease.
    Birkmayer W; Birkmayer GJ
    Ann Clin Lab Sci; 1989; 19(1):38-43. PubMed ID: 2644889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of endogenous L-dopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide (NADH) and nicotinamide adenine dinucleotidephosphate (NADPH).
    Birkmayer GJ; Birkmayer W
    Acta Neurol Scand Suppl; 1989; 126():183-7. PubMed ID: 2618590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer's disease with stabilized oral nicotinamide adenine dinucleotide: a randomized, double-blind study.
    Demarin V; Podobnik SS; Storga-Tomic D; Kay G
    Drugs Exp Clin Res; 2004; 30(1):27-33. PubMed ID: 15134388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.
    Birkmayer JG
    Ann Clin Lab Sci; 1996; 26(1):1-9. PubMed ID: 8834355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical benefit of NADH as stimulator of endogenous L-dopa biosynthesis in parkinsonian patients.
    Birkmayer W; Birkmayer JG; Vrecko K; Paletta B
    Adv Neurol; 1990; 53():545-9. PubMed ID: 2239495
    [No Abstract]   [Full Text] [Related]  

  • 10. On the safety of reduced nicotinamide adenine dinucleotide (NADH).
    Birkmayer JG; Nadlinger KF; Hallström S
    J Environ Pathol Toxicol Oncol; 2004; 23(3):179-94. PubMed ID: 15312041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is NADH effective in the treatment of Parkinson's disease?
    Swerdlow RH
    Drugs Aging; 1998 Oct; 13(4):263-8. PubMed ID: 9805207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of stabilized, orally absorbable, reduced nicotinamide adenine dinucleotide (NADH): a 26-week oral tablet administration of ENADA/NADH for chronic toxicity study in rats.
    Birkmayer JG; Nadlinger K
    Drugs Exp Clin Res; 2002; 28(5):185-92. PubMed ID: 12635493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome.
    Santaella ML; Font I; Disdier OM
    P R Health Sci J; 2004 Jun; 23(2):89-93. PubMed ID: 15377055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravenous and oral treatment with amantadine sulfate in Parkinson disease].
    Brenner M; Haass A; Jacobi P; Schimrigk K
    Nervenarzt; 1988 Mar; 59(3):180-4. PubMed ID: 3374720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome.
    Forsyth LM; Preuss HG; MacDowell AL; Chiazze L; Birkmayer GD; Bellanti JA
    Ann Allergy Asthma Immunol; 1999 Feb; 82(2):185-91. PubMed ID: 10071523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease.
    Stocchi F; Ruggieri S; Carta A; Ryatt J; Quinn N; Jenner P; Marsden CD; Agnoli A
    Mov Disord; 1992; 7(3):249-56. PubMed ID: 1620143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic stimulation and enzymatic inhibition in Parkinson's disease.
    Nagatsu T
    Acta Neurol Scand Suppl; 1993; 146():14-7. PubMed ID: 8101411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
    Freed CR; Greene PE; Breeze RE; Tsai WY; DuMouchel W; Kao R; Dillon S; Winfield H; Culver S; Trojanowski JQ; Eidelberg D; Fahn S
    N Engl J Med; 2001 Mar; 344(10):710-9. PubMed ID: 11236774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of metabolic fates of nicotinamide, NAD+ and NADH administered orally and intraperitoneally; characterization of oral NADH.
    Kimura N; Fukuwatari T; Sasaki R; Shibata K
    J Nutr Sci Vitaminol (Tokyo); 2006 Apr; 52(2):142-8. PubMed ID: 16802695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of NADH on dopamine release in rat striatum.
    Pearl SM; Antion MD; Stanwood GD; Jaumotte JD; Kapatos G; Zigmond MJ
    Synapse; 2000 May; 36(2):95-101. PubMed ID: 10767056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.